NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer
Adenocarcinoma of the Pancreas

Interventions: Drug: alvocidib
Drug: docetaxel

First Posted Date: 2006-05-31

Last Posted Date: 2014-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00331682

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

Phase 2

Completed

Conditions: Embryonal Childhood Rhabdomyosarcoma
Recurrent Adult Soft Tissue Sarcoma
Adult Synovial Sarcoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Osteosarcoma
Adult Rhabdomyosarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Childhood Soft Tissue Sarcoma
Recurrent Neuroblastoma
Recurrent Wilms Tumor and Other Childhood Kidney Tumors

Interventions: Drug: ixabepilone

First Posted Date: 2006-05-31

Last Posted Date: 2014-11-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT00331643

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Previously Treated Myelodysplastic Syndromes
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Promyelocytic Leukemia (M3)
Blastic Phase Chronic Myelogenous Leukemia
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Interventions: Drug: vorinostat
Drug: idarubicin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-05-31

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00331513

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Phase 1

Completed

Conditions: Adenocarcinoma of the Prostate
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: mitoxantrone hydrochloride
Drug: ixabepilone
Drug: prednisone

First Posted Date: 2006-05-31

Last Posted Date: 2017-10-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00331344

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: doxorubicin hydrochloride
Drug: vorinostat
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-05-31

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00331955

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: vorinostat
Other: laboratory biomarker analysis

First Posted Date: 2006-05-26

Last Posted Date: 2014-05-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00330161

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

Phase 2

Completed

Conditions: Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Metastatic Osteosarcoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Osteosarcoma
Stage I Adult Soft Tissue Sarcoma
Stage II Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Drug: sorafenib tosylate
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: computed tomography
Procedure: dynamic contrast-enhanced magnetic resonance imaging

First Posted Date: 2006-05-26

Last Posted Date: 2014-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00330421

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia

Phase 2

Completed

Conditions: Oral Leukoplakia
Oropharyngeal Cancer
Tongue Cancer
Lip and Oral Cavity Cancer

Interventions: Other: placebo
Drug: Bowman-Birk inhibitor concentrate
Other: laboratory biomarker analysis

First Posted Date: 2006-05-26

Last Posted Date: 2014-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 325

Registration Number: NCT00330382

Locations: 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Phase 2

Completed

Conditions: Extraocular Extension Melanoma
Iris Melanoma
Recurrent Intraocular Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Metastatic Intraocular Melanoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: sorafenib tosylate

First Posted Date: 2006-05-25

Last Posted Date: 2014-07-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00329641

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

Phase 1

Completed

Conditions: Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Glioblastoma

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Conventional Surgery
Drug: Sorafenib Tosylate
Drug: Temsirolimus

First Posted Date: 2006-05-25

Last Posted Date: 2018-10-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 115

Registration Number: NCT00329719

Locations: 🇺🇸
Graham Hospital Association, Canton, Illinois, United States
🇺🇸
Illinois CancerCare-Macomb, Macomb, Illinois, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 186 locations

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma